[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.75.58. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 236
Citations 0
Comment & Response
February 13, 2020

Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer—Reply

Author Affiliations
  • 1Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York
JAMA Oncol. Published online February 13, 2020. doi:10.1001/jamaoncol.2019.6712

In Reply Lee’s assertion that clinical outcomes cannot be compared between the National Surgical Adjuvant Breast and Bowel Project (NSABP) B20 trial and the Trial Assigning Individualized Options for Treatment (TAILORx) reflects a fundamental misunderstanding of the methods and major findings of our report1 describing clinical outcomes in 1389 women with a recurrence score (RS) of 26 to 100 assigned to receive chemoendocrine therapy in the TAILORx trial. We did not compare outcomes in these 2 cohorts in the results but rather the estimated outcomes had the TAILORx cohort received endocrine therapy alone rather than chemoendocrine therapy based on the chemotherapy treatment effect observed in the NSABP B20 trial. Our intention was not to prove the use of the Oncotype DX RS assay (Genomic Health) in predicting chemotherapy benefits that had already been established in prior cohorts and informed current practice guidelines but rather to provide information regarding potential chemotherapy benefits that could be realized in such a population treated with contemporary therapies.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×